Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No exception for Agennix as sepsis claims another hopeful victim - talactoferrin

This article was originally published in Scrip

Executive Summary

Shares of Agennix succumbed to their biggest percentage fall in more than two years in Frankfurt trading upon an announcement that it was halting the Phase II/III OASIS trial of its oral immunotherapy talactoferrin (recombinant human lactoferrin) for severe sepsis. The trial showed that talactoferrin plus standard of care had a greater 28-day all-cause mortality than standard of care alone. Talactoferrin is the company's lead programme, and Agennix declined 30% to €1.88 at the close of trading.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts